Top Markets
#1 MowCat MowCat +26.91%
#2 Wrapped STX (Velar) Wrapped STX (Velar) +17.61%
#3 Versatize Coin Versatize Coin +16.67%
#4 Prom Prom +14.34%
#5 QuantixAI QuantixAI +12.95%
#6 Pons Pons +12.04%
#7 StonkBroker StonkBroker +10.46%
#8 Wrapped NXM Wrapped NXM +10.13%
#9 Nesa Nesa +9.89%
#10 Collector Crypt Collector Crypt +8.81%
Coin of the day
MowCat MowCat
Innstillinger
Språk
NORSK
Valuta
USD
Tema
Sunho Biologics, Inc. Sunho Biologics, Inc.

Sunho Biologics, Inc.

2898
Rangering i aksjer #20679
Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering,... Sunho Biologics, Inc. is a biopharmaceutical firm dedicated to discovering, advancing, and bringing to market biological therapies. These treatments are designed to influence the body's immune system, both its inherent and adaptive responses, thereby altering the immune microenvironment. Among its portfolio is IAH0968, a monoclonal antibody specifically engineered to enhance antibody-dependent cell-mediated cytotoxicity, currently undergoing Phase II clinical trials for the treatment of biliary tract carcinoma and colorectal cancer. The company also develops IAP0971 and IAE0972, a pair of immunocytokines that have successfully concluded Phase I clinical trials for various advanced solid tumors, notably non-small cell lung cancer and colorectal cancer. Sunho Biologics also boasts a robust pipeline of early-stage assets. These include IBB0979, an immunocytokine targeting solid tumors; IBC0966, a dual-action fusion protein (anti-PD-L1 antibody-signal regulatory protein) in clinical development, designed to elicit tumor-specific immune responses; IBD0333, aimed at tumor cells; IAN0982, another oncology candidate; and immunosuppressants ISH0988 and ISH0613, which are being explored for autoimmune conditions. Established in 2018, the company operates from its headquarters in Huzhou, China, and functions as a subsidiary of Sunho Wisdom Investments Limited.
Aksjekurs
$0.81744861
Sist synkronisert: 2026-04-02
Markedsverdi
$124.61M
Endring (1 dag)
0.00%
Endring (1 år)
-7.82%
Land
CN
Handel Sunho Biologics, Inc. (2898)

Kategori

Healthcare
P/E-forhold for Sunho Biologics, Inc. (2898)
P/E-forhold per 2026 TTM: 0
Ifølge Sunho Biologics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for Sunho Biologics, Inc. fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.